Login| Sign Up| Help| Contact|

Patent Searching and Data


Title:
USE OF CARBAMATE COMPOUND FOR PREVENTING, ALLEVIATING OR TREATING ABSENCE SEIZURE OR EPILEPSY SHOWING ABSENCE SEIZURE
Document Type and Number:
WIPO Patent Application WO/2019/098628
Kind Code:
A1
Abstract:
The present invention relates to a use of a carbamate compound represented by chemical formula 1, or a pharmaceutically acceptable salt, a solvate or a hydrate thereof for preventing, alleviating or treating absence seizure or epilepsy showing absence seizure.

Inventors:
SHIN HYE WON (KR)
Application Number:
KR2018/013761
Publication Date:
May 23, 2019
Filing Date:
November 13, 2018
Export Citation:
Click for automatic bibliography generation   Help
Assignee:
SK BIOPHARMACEUTICALS CO LTD (KR)
International Classes:
A61K31/41; A61K31/16
Domestic Patent References:
WO2006112685A12006-10-26
WO2010150946A12010-12-29
WO2011046380A22011-04-21
WO2010150946A12010-12-29
Foreign References:
KR20080005437A2008-01-11
KR20120087124A2012-08-06
KR20100137389A2010-12-30
Other References:
BIALER, M. ET AL.: "Progress Report on new Antiepileptic Drugs: A Summary of the Twelfth Eilat Conference (EILAT XII", EPILEPSY RESEARCH, vol. 1, no. 11, 2015, pages 85 - 141, XP055608941
GOLYALA, A. ET AL.: "Drug Development for Refractory Epilepsy: The Past 25 Years and Beyond", SEIZURE, vol. 44, January 2017 (2017-01-01), pages 147 - 156, XP029901803, DOI: doi:10.1016/j.seizure.2016.11.022
GLAUSER ET AL.: "Ethosuximide, Valproic Acid, and Lamotrigine in Childhood Absence Epilepsy", NEW ENGLAND JOURNAL OF MEDICINE, vol. 362, no. 9, 2010, pages 790 - 9
KNAKE ET AL.: "Tiagabine-induced absence status in idiopathic generalized epilepsy", EUROPEAN JOURNAL OF EPILEPSY, vol. 8, no. 5, 8 August 1999 (1999-08-08), pages 314 - 317
DEPAULIS ET AL.: "The genetic absence epilepsy rat from Strasbourg as a model to decipher the neuronal and network mechanisms of generalized idiopathic epilepsies", J NEUROSCI METHODS, vol. 260, 15 February 2016 (2016-02-15), pages 159 - 74, XP029405999, DOI: 10.1016/j.jneumeth.2015.05.022
DEDEURWAERDERE ET AL.: "Fluctuating and constant valproate administration gives equivalent seizure control in rats with genetic and acquired epilepsy", SEIZURE, vol. 20, no. 1, January 2011 (2011-01-01), pages 72 - 9, XP027570829
NEHLIG ET AL.: "Cerebral energy metabolism in rats with genetic absence epilepsy is not correlated with the pharmacological increase or suppression of spike-wave discharges", BRAIN RES., vol. 618, no. 1, 30 July 1993 (1993-07-30), pages 1 - 8, XP024282154, DOI: 10.1016/0006-8993(93)90421-I
WALLENGREN ET AL.: "Aggravation of absence seizures by carbamazepine in a genetic rat model does not induce neuronal c-Fos activation", CLIN NEUROPHARMACOL., vol. 28, no. 2, March 2005 (2005-03-01), pages 60 - 5
GURBANOVA ET AL.: "Effect of systemic and intracortical administration of phenytoin in two genetic models of absence epilepsy", BR J PHARMACOL., vol. 148, no. 8, August 2006 (2006-08-01), pages 1076 - 82
VARTANIAN ET AL.: "Activity profile of pregabalin in rodent models of epilepsy and ataxia", EPILEPSY RES., vol. 68, no. 3, March 2006 (2006-03-01), pages 189 - 205, XP025114989, DOI: 10.1016/j.eplepsyres.2005.11.001
KLITGAARD ET AL.: "Use of epileptic animals for adverse effect testing", EPILEPSY RES., vol. 50, no. 1-2, June 2002 (2002-06-01), pages 55 - 65
VAN LUIJTELAAR ELDRINKENBURG WHVAN RIJN CMCOENEN AM: "Rat models of genetic absence epilepsy: what do EEG spike-wave discharges tell us about drug effects?", METHODS FIND EXP CLIN PHARMACOL., vol. 24, no. D, 2002, pages 65 - 70
Attorney, Agent or Firm:
HANSUNG INTELLECTUAL PROPERTY (KR)
Download PDF: